Clinical trials: Blood Plasma Therapy
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Lung Injury
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
- Trial name
- NCT04848272
- Testing
- Lanadelumab, Saline control
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- St Vincent's Institute of Medical Research
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Multiple Myeloma
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
There is a great need for treatment options in patients with multiple myeloma (MM) after failure of the lenalidomide/dexamethasone regimen as there is no established standard active therapy for these patients.
- Trial name
- NCT01555281
- Testing
- Nelfinavir, Lenalidomide, Dexamethasone
- Where
- 11 sites in Italy, Switzerland
- Volunteers
- 33 people
- Sponsor
- Swiss Cancer Institute
Secondary Immunodeficiencies (SID)
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
- Trial name
- QS-SID (NCT04172467)
- Testing
- non-interventional retrospective epidemiological observational study
- Where
- Germany
- Volunteers
- 1,086 people
- Sponsor
- AIO-Studien-gGmbH
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
Glossopharyngeal Neuralgia, Pulsed Radiofrequency
Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet Rich Plasma to Treat Idiopathic Glossopharyngeal Neuralgia (GPN)
To investigate the efficacy and safety of the application of PRF combined PRP to the for the treatment of GPN.
- Conditions
- Glossopharyngeal Neuralgia, Pulsed Radiofrequency, Platelet Rich Plasma
- Trial name
- NCT06931457
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Beijing Tiantan Hospital
Multiple Myeloma
A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
The scientific approach behind this study is to develop novel anti-cancer therapeutic vaccine to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes populations and can be be applicable to the…
- Trial name
- NCT01232712
- Testing
- ImMucin, hGM-CSF
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Vaxil Therapeutics Ltd.
HIV Infections, Lipoatrophy
Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
Background: Stavudine-containing regimens are associated with a potential for lipoatrophy and dyslipidemia. We assessed the safety and efficacy of reducing the dose of stavudine compared to switching to tenofovir or maintaining…
- Trial name
- NCT00312832
- Testing
- switching; dose reduction
- Volunteers
- 60 people
- Sponsor
- Hospital Clinic of Barcelona
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00844428)
- Testing
- eculizumab
- Where
- 13 sites in Canada, France and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Relapsed/Refractory Multiple Myeloma(MM)
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple…
- Trial name
- NCT07100067
- Testing
- LCAR- F33S cells intravenous infusion
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Nanjing Legend Biotech Co.
Osteopenia, Osteoporosis
FREE Study - Fracture Reduction Evaluation
The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral body compression fractures.
- Conditions
- Osteopenia, Osteoporosis, Multiple Myeloma, Bone Neoplasms
- Trial name
- NCT00211211
- Testing
- Balloon Kyphoplasty
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Medtronic Spine LLC
Multiple Myeloma
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
The combination lenalidomide plus low-dose dexamethasone (Rd) is an active treatment for Multiple Myeloma (MM) patients, both at diagnosis and at relapse.
- Trial name
- PO-3887 (NCT03440411)
- Testing
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione EMN Italy Onlus
Knee Osteoarthritis
Comparing Efficacy of PRP Combined With Different Hyaluronan for the Treatment of Knee Osteoarthritis
Either PRP or HA is each effective for treating knee OA. However, the efficacy of combined PRP and HA injections remains unknown clinically.
- Trial name
- NCT04931719
- Testing
- PRP+Artz group, PRP+ HYAJOINT Plus group
- Where
- Taiwan
- Volunteers
- 95 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Hemophilia A, Severe
An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients
This is a prospective, multicenter, open-label study to assess efficacy, safety, pharmacokinetics (PK), and immunogenicity of human plasma-derived Factor VIII (FVIII) in previously treated patients (PTPs) with severe hemophilia…
- Trial name
- NCT06738901
- Testing
- SKP-0141
- Volunteers
- 55 people
- Sponsor
- SK Plasma Co., Ltd.
Multiple Myeloma, Complication
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by…
- Trial name
- PASCA -MM (NCT05947136)
- Testing
- Interpretation of the results from the detection visit, Explaining detection results and referrals to the patient, Early medical care through the network
- Where
- 6 sites in France
- Volunteers
- 204 people
- Sponsor
- Centre Leon Berard
Erectile Dysfunction
A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction
Erectile dysfunction (ED) is a common condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual activity.
- Trial name
- NCT07544537
- Testing
- Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC), Autologous Platelet-Rich Plasma (4 mL), Autologous Platelet-Rich Plasma (6 mL)
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- National Scientific Medical Center, Kazakhstan
Waldenstrom Macroglobulinemia, Treatment Naive
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities.
- Trial name
- VIWA-1 (NCT05099471)
- Testing
- Venetoclax; Rituximab, DRC
- Where
- 14 sites in Germany, Greece
- Volunteers
- 80 people
- Sponsor
- Christian Buske
Waldenström Macroglobulinemia
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance…
- Trial name
- BDH-WM02 (NCT02844309)
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acetabular Labrum Tear, Femoro Acetabular Impingement
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
Femoro-acetabular impingement is a well known cause of damage to the acetabular labrum and chondrolabral junction. Additionally, it has been proposed that disruption of hip biomechanics resulting from a labral tear causes a…
- Conditions
- Acetabular Labrum Tear, Femoro Acetabular Impingement, Chondral Defect, Bone Marrow Aspirate Concentrate
- Trial name
- NCT03909139
- Testing
- BMAC
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Massachusetts General Hospital